Table 2.

Overall findings at time of onset, 3 and 6-month follow-up.

Baseline characteristics all cases of myocarditis	Time of symptom onset	3-month follow-up	6-month follow-up	12-month follow-up	P Value
CMR/Echocardiography	n = 30	n = 30	n = 26	n = 19
Mean LVEF (±SD)	58 (±7.44)	59 (±6)	59.4 (±4.8)	58 (±5.3)	NS
Resting ECG	n = 30	n = 30	n = 26	n = 19
Number of malignant arrhythmias	0	1	0	0	NS
Number of benign arrhythmias	8	6	4	4	NS
48-h-Holter ECG	n = 0	n = 30	n = 26	n = 19
Number of malignant arrhythmias	/	1	0	0	NS
Number of benign arrhythmias	/	6	6	4	NS
Median APC/QRS % (IQR)	/	0.0172 (0.008–0-047)	0.036 (±0.055%)	0.034 (0.002–0.06	NS
Median PVC/QRS % (IQR)	/	0.008 (0–0.0029)	0. 16% (±0.782%)	0.0026 (0–0.02)	NS
Exercise stress test	n = 0	n = 29	n = 25	n = 19
Mean performance, watts (±SD)	/	190 (±67)	195 (±75)	206 (±75)	NS
Mean % of predicted maximum watt	/	95% (±27)	98 (±26)	105 (±26)	NS
Number of malignant arrhythmias	/	0	0	0	NS
Laboratory results (median)	n = 30	n = 30	n = 26	n = 19
Mb, ng/l (IQR)	32 (0–111)	27 (0–40)	22.7 (±31.1)	27 (0–43)	0.011
TnT-hs, ng/l (IQR)	350 (88–1104)	2.5 (0–7)	4.4 (±7.5)	0 (0–7)	<0.001
CK, U/l (IQR)	238 (128–587)	97 (66–156)	130.3 (±63)	119 (75–193)	0.001
NT-proBNP, ng/l (IQR)	251 (45–676)	30 (11–44)	63 (±84)	38 (13–121)	0.05
CRP, mg/l (IQR)	21 (3–66)	0.7 (0.4–2.6)	1.6 (±1.8)	0.9 (0.5–1.6)	<0.001
Lc, G/L (IQR)	7 (6–9)	6.8 (5.9–7.2)	5.9 (±2.3)	6 (5.6–7.6)	NS

Abbreviations: CMR = cardiac magnetic resonance imaging; SD = standard deviation; ECG = electrocardiogram; APC = atrial premature contraction; TnT-hs = high sensitivity troponin T, CK = creatine kinase; CRP = C-reactive protein; Lc = leukocytes; LVEF = left ventricular ejection fraction; Mb = myoglobin; NT-proBNP = NT-pro brain natriuretic peptide; NS = not significant; IQR = interquartile range; PVC = premature ventricular contraction